Drugs / AZD6370
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00690287 | Feb → Jun 2008 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD6370 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00690287 ↗ |
| Action | Activate | “The glucokinase activator AZD6370 decreases fasting and postprandial glucose in type 2 diabetes mellitus patients” PMID 23010558 ↗ Sep 2012 |
| Route | Oral | “patients received a single oral dose of AZD6370 (20, 60 or 180 mg)” PMID 23010558 ↗ Sep 2012 |